Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.
Nationwide Children's Hospital, 700 Children's Drive, Columbus, Ohio 43205, United States.
J Med Chem. 2021 Aug 12;64(15):11229-11246. doi: 10.1021/acs.jmedchem.1c00608. Epub 2021 Jul 22.
In this paper, we applied an innovative nuclear magnetic resonance (NMR)-guided screening and ligand design approach, named focused high-throughput screening by NMR (fHTS by NMR), to derive potent, low-molecular-weight ligands capable of mimicking interactions elicited by ephrin ligands on the receptor tyrosine kinase EphA4. The agents bind with nanomolar affinity, trigger receptor activation in cellular assays with motor neurons, and provide remarkable motor neuron protection from amyotrophic lateral sclerosis (ALS) patient-derived astrocytes. Structural studies on the complex between EphA4 ligand-binding domain and a most active agent provide insights into the mechanism of the agents at a molecular level. Together with preliminary in vivo pharmacology studies, the data form a strong foundation for the translation of these agents for the treatment of ALS and potentially other human diseases.
在本文中,我们应用了一种创新的基于核磁共振(NMR)的筛选和配体设计方法,命名为基于 NMR 的聚焦高通量筛选(fHTS by NMR),以获得能够模拟受体酪氨酸激酶 EphA4 上的 Ephrin 配体所引发的相互作用的、有效且低分子量的配体。这些化合物具有纳摩尔亲和力,在针对运动神经元的细胞测定中触发受体激活,并能显著保护运动神经元免受肌萎缩侧索硬化症(ALS)患者衍生的星形胶质细胞的侵害。EphA4 配体结合域与最活跃的化合物之间的结构研究为这些化合物在分子水平上的作用机制提供了深入的了解。与初步的体内药理学研究一起,这些数据为将这些化合物用于治疗 ALS 以及可能的其他人类疾病奠定了坚实的基础。